{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:28:05Z","timestamp":1794472085181,"version":"4.9.1"},"posted":{"date-parts":[[2023,10,19]]},"group-title":"In Review","reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,10,10]]},"abstract":"<title>Abstract<\/title>\n        <p>Purpose\n To identify and quantify the reasons why acute coronary syndrome (ACS) patients undergoing stenting at University of New Mexico Hospital were prescribed sub-optimal dual antiplatelet therapy (DAPT) at discharge, and to identify practice patterns that could potentially lead to improved DAPT treatment for these patients.\nMethods\n We reviewed electronic medical records and cardiac catheterization records of 326 patients who underwent PCI at UNMH between January 1, 2021, and June 30, 2022 and identified 229 ACS patients who survived until discharge. Demographic and clinical characteristics relevant to P2Y<sub>12<\/sub> selection were obtained from a review of medical records. Pharmacists\u2019 notes that documented their efforts to get appropriate insurance coverage and reasons for discharge on clopidogrel rather than ticagrelor were reviewed. Patients discharged on aspirin and clopidogrel underwent review of medical records and cardiac catheterization lab records to determine if the discharge P2Y<sub>12<\/sub> drug was appropriate. Reasons for inappropriately discharge on clopidogrel were categorized as cost\/insurance, patient preference, concern for daily adherence to a twice-daily medication, and on clopidogrel before PCI and not switched to ticagrelor afterward.\nResults\n The 229 ACS patients included (38.0%, n\u2009=\u200987) appropriately discharged on ticagrelor\/prasugrel, (27.5%, n\u2009=\u200963) appropriately discharged on clopidogrel, (32.8%, n\u2009=\u200975) inappropriately discharged on clopidogrel, and (1.7%, n\u2009=\u20094) not discharged on a P2Y<sub>12<\/sub> inhibitor. For patients inappropriately discharged on clopidogrel (n\u2009=\u200975), the most common reasons were cost or lack of insurance (n\u2009=\u200956) and clinical inertia (taking clopidogrel before PCI and maintained on it afterward) (n\u2009=\u200917). Inappropriate DAPT at discharge correlated with lack of insurance (90.5% compared to 39.7% in patients with insurance, P\u2009&lt;\u20090.001) but not with ethnicity.\nConclusion\n At the University of New Mexico, a safety-net hospital, increasing financially restricted access to ticagrelor could help up to 24.5% of ACS patients reduce their risk of ischemic events. For patients admitted on clopidogrel DAPT, upgrading to ticagrelor could reduce ischemic risk in 7.4% of ACS patients. Expanding healthcare insurance coverage might redue sub-optimal DAPT coverage.<\/p>","DOI":"10.21203\/rs.3.rs-3425525\/v1","type":"posted-content","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T16:56:44Z","timestamp":1697734604000},"source":"Crossref","is-referenced-by-count":2,"title":["Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy:\u00a0 A Single Center Experience"],"prefix":"10.21203","author":[{"given":"Jeffrey","family":"Booker","sequence":"first","affiliation":[{"name":"University of New Mexico School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"alexander","family":"Nihart","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"matthew","family":"Campen","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Medrano-Rodriguez","sequence":"additional","affiliation":[{"name":"University of New Mexico School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-533X","authenticated-orcid":false,"given":"James","family":"Blankenship","sequence":"additional","affiliation":[{"name":"University of New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.513S","author":"Harrington RA","year":"2004","unstructured":"Harrington RA, Becker RC, Ezekowitz M et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S-548S. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.513S."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl SR","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411\u201320. 10.1001\/jama.288.19.2411.","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.12659\/MSM.902120","article-title":"Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes","volume":"22","author":"Dong P","year":"2016","unstructured":"Dong P, Yang X, Bian S. Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes. Med Sci Monit Int Med J Exp Clin Res. 2016;22:4929\u201336. 10.12659\/MSM.902120.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40256-019-00373-1","article-title":"Efficacy and safety of clopidogrel, prasugrel and ticagrelor in ACS patients treated with PCI: a propensity score analysis of the RENAMI and BleeMACS registries","volume":"20","author":"Peyracchia M","year":"2020","unstructured":"Peyracchia M, Saglietto A, Biol\u00e8 C, et al. Efficacy and safety of clopidogrel, prasugrel and ticagrelor in ACS patients treated with PCI: a propensity score analysis of the RENAMI and BleeMACS registries. Am J Cardiovasc Drugs Drugs Devices Interv. 2020;20:259\u201369. 10.1007\/s40256-019-00373-1.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e0219676","DOI":"10.1371\/journal.pone.0219676","article-title":"Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry","volume":"14","author":"Marcucci R","year":"2019","unstructured":"Marcucci R, Patti G, Calabr\u00f2 P, et al. Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS ONE. 2019;14:e0219676. doi.org\/10.1371\/journal.pone.0219676.","journal-title":"PLoS ONE"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/clc.23536","article-title":"Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta-analysis","volume":"44","author":"Chen W","year":"2021","unstructured":"Chen W, Zhang C, Zhao J, et al. Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta-analysis. Clin Cardiol. 2021;44:488\u201394. 10.1002\/clc.23536.","journal-title":"Clin Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton JS","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21\u2013129. doi.org\/10.1016\/j.jacc.2021.09.006.","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli M","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360. 10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e015990","DOI":"10.1161\/JAHA.119.015990","article-title":"Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish Coronary Angiography and Angioplasty Registry. Journal of the American Heart Association","volume":"9","author":"V\u00f6lz S","year":"2020","unstructured":"V\u00f6lz S, Petursson P, Odenstedt J, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish Coronary Angiography and Angioplasty Registry. Journal of the American Heart Association. J Am Heart Assoc. 2020;9:e015990. 10.1161\/JAHA.119.015990.","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/imj.13041","article-title":"Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"46","author":"Yudi MB","year":"2016","unstructured":"Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46:559\u201365. doi.org\/10.1111\/imj.13041.","journal-title":"Intern Med J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1753944712468627","article-title":"Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports","volume":"7","author":"DiNicolantonio JJ","year":"2013","unstructured":"DiNicolantonio JJ, Serebruany VL. Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. Ther Adv Cardiovasc Dis. 2013;7:5\u20139. 10.1177\/.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijcard.2014.02.028","article-title":"Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients","volume":"173","author":"Gaubert M","year":"2014","unstructured":"Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014;173:120\u20131. doi.org\/10.1016\/j.ijcard.2014.02.028.","journal-title":"Int J Cardiol"},{"key":"ref13","volume-title":"Health insurance coverage in the United States: 2021","author":"Keisler-Starkey K","year":"2021","unstructured":"Keisler-Starkey K, Bunch LN. Health insurance coverage in the United States: 2021. Washington DC: US Census Bureau; 2021."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndrome N","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome N. Engl J Med. 2009;361:1045\u201357. 10.1056\/NEJMoa0904327.","journal-title":"Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese EP","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150\u201360. 10.1161\/CIRCULATIONAHA.120.046786.","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","article-title":"Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"324","author":"You SC","year":"2020","unstructured":"You SC, Rho Y, Bikdeli B, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640\u201350. 10.1001\/jama.2020.16167.","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"zuab020103","DOI":"10.1093\/ehjacc\/zuab020.103","article-title":"Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis","volume":"10","author":"Abdul Razzack A","year":"2021","unstructured":"Abdul Razzack A, Pothuru S, Hussain N, et al. Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis. Eur Heart J Acute Cardiovasc Care. 2021;10:zuab020103. https:\/\/doi.org\/10.1093\/ehjacc\/zuab020.103.","journal-title":"Eur Heart J Acute Cardiovasc Care"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3425525\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3425525\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T21:37:05Z","timestamp":1715722625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3425525\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3425525\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s10557-024-07563-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,10,19]]},"subtype":"preprint"}}